Tci Wealth Advisors, Inc. Arvinas, Inc. Transaction History

Tci Wealth Advisors, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 03, 2023	BUY	$26.15 - $37.26 $4,236 - $6,036	162 New	162 $4,000
Q2 2022 Jul 19, 2022	SELL	$36.01 - $74.24 $2,808 - $5,790	-78 Reduced 41.94%	108 $5,000
Q1 2022 Apr 29, 2022	SELL	$60.27 - $81.57 $120 - $163	-2 Reduced 1.06%	186 $13,000
Q4 2021 Jan 24, 2022	BUY	$65.85 - $96.21 $4,148 - $6,061	63 Added 50.4%	188 $15,000
Q3 2021 Oct 29, 2021	BUY	$73.2 - $107.87 $4,318 - $6,364	59 Added 89.39%	125 $10,000
Q2 2021 Aug 02, 2021	BUY	$60.45 - $84.26 $1,571 - $2,190	26 Added 65.0%	66 $5,000
Q1 2021 Apr 29, 2021	BUY	$58.19 - $91.37 $2,327 - $3,654	40 New	40 $3,000

224

70.9M

1.52M

346K

Ticker ARVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,205,300
Market Cap $945M
Description
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...

Get notified when there are updates to the investment portfolio of Tci Wealth Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Tci Wealth Advisors, Inc. with notifications on news.